Therapeutic Asset Ratings
164 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Jnj-87801493
Myelodysplastic Syndrome
Janssen Research & Development, LLC
P1
C
(37)
Jnj-87801493
Neoplasm
Janssen Research & Development, LLC
P1
C
(37)
Jnj-87801493
Solid Tumor, Adult
Janssen Research & Development, LLC
P1
C
(37)
Jnj-87890387
Neoplasm
Janssen Research & Development, LLC
P1
C
(37)
SAFIMALTIB
Myelodysplastic Syndrome
Janssen Research & Development, LLC
P1
C
(37)
SAFIMALTIB
Neoplasm
Janssen Research & Development, LLC
P1
C
(37)
SAFIMALTIB
Solid Tumor, Adult
Janssen Research & Development, LLC
P1
C
(37)
Jnj-75276617
Acute Myeloid Leukemia
Janssen Research & Development, LLC
P1
C
(36)
Jnj-87890387
Cancer
Janssen Research & Development, LLC
P1
C
(36)
Masofaniten
Prostate Neoplasm
Janssen Research & Development, LLC
P1
C
(32)
Aticaprant
Schizophrenia
Janssen Research & Development, LLC
P1
D
(30)
Jnj-79635322
AL Amyloidosis
Janssen Research & Development, LLC
P1
NR
(0)
Jnj-88998377
B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
P1
NR
(0)
Jnj-89862175
Cancer
Janssen Research & Development, LLC
P1
NR
(0)
Showing 151 to 164 of 164 assets
Previous
Page 7 of 7
Next
